profit from every $100 of sales.
$0$100
Sagimet Biosciences
$11.41+4.78% today
+34.2% in 1 year
1-year low $4.551-year high $11.41
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Sagimet Biosciences sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$51.0 million of profit last year.
SalesProfit
Sagimet Biosciences vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Sagimet Biosciences | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Sagimet Biosciences's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 2 | 0 | 0 | |
| – | – | – | – | |
| -31 | -31 | -54 | -57 | |
| -31 | -31 | -54 | -57 | |
| -30 | -28 | -46 | -51 | |
| -1.38 | -2.66 | -1.45 | -1.58 | |
| – | – | – | – | |
| – | -1,537.0% | – | – | |
| – | -1,393.8% | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 33 | 97 | 160 | 116 |
| Cash | 0 | 75 | 76 | 35 |
| Total debt | 0 | 0 | 0 | 0 |
| Total liabilities | 220 | 6 | 4 | 5 |
| -187 | 91 | 156 | 111 | |
| 22 | 10 | 31 | 32 | |
| – | -26.6% | -27.6% | -40.3% | |
| 16.3% | -30.6% | -29.2% | -45.8% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -24 | -24 | -42 | -46 | |
| – | – | – | – | |
| -24 | -24 | -42 | -46 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 2 | 5 | 5 | 6 |
Valuation
- –
- –
- –
- 2.1×
- 404.5×
- –
- –
- -2.9%
- -3.4%
- 0.0%
Profitability
- 0.0%
- -1,537.0%
- -1,393.8%
- 0.0%
- -47.5%
- -14.8%
- -37.6%
- -40.4%
- -47.6%
- –
Growth
- –
- –
- −7.6%
- –
- +9.9%
Financial health
- -2.4×
- 0.00
- 0.0%
- –
- 20.34
- 20.34
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 8%of 958
Bottom 24%of 987
What analysts expect
- Average price target
- $8.00
- Range
- $8.00 – $8.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 12, 2026 | -0.33 | -0.39 | +15.4% |
| Mar 11, 2026 | -0.29 | -0.43 | +32.6% |
| Nov 13, 2025 | -0.40 | -0.41 | +2.4% |
| Aug 13, 2025 | -0.32 | -0.52 | +38.5% |
| May 8, 2025 | -0.56 | -0.79 | +29.1% |
| Mar 12, 2025 | -0.50 | -0.65 | +23.1% |
| Nov 14, 2024 | -0.45 | -0.47 | +4.3% |
| Aug 14, 2024 | -0.25 | -0.34 | +26.5% |
News
Sagimet closes down after acne drug denifanstat data, closing of stock offeringSeeking Alpha · Oct 1, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
26No pass
Benjamin Graham
52No pass
Philip Fisher
33No pass
Peter Lynch
10No pass
Joel Greenblatt
0No pass
Charlie Munger
29No pass
Terry Smith
28No pass
Questions about Sagimet Biosciences
Is Sagimet Biosciences a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Sagimet Biosciences AI analysis
What does Sagimet Biosciences do?
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. It is in Biotechnology.
Does Sagimet Biosciences pay a dividend?
No. Sagimet Biosciences does not pay a dividend at the moment.
Is Sagimet Biosciences stock halal?
Yes. Sagimet Biosciences passes our halal screen: its business is permitted and its debt is under 0.1% of its market value, under the 30% limit. How we check
How has Sagimet Biosciences stock done over the past year?
Up 34.2% over the past twelve months, to $11.41. It traded between $4.55 and $11.41, close to its high.
Who are Sagimet Biosciences's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Sagimet Biosciences's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.